2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists
申请人:Eli Lilly and Company
公开号:US08202873B2
公开(公告)日:2012-06-19
The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety:
where A and B are each independently —C(H)═ or —N═, provided that at least one of A and B is —N═, n is 1-3, m is 0-3, and R1-4 are as defined herein.
本发明提供了式I的选择性5-HT7受体拮抗剂化合物及其在治疗偏头痛、持续性疼痛和焦虑症方面的用途:其中A和B分别独立地为—C(H)═或—N═,但至少其中之一为—N═,n为1-3,m为0-3,R1-4如本文所定义。